

Citation for published version:

Freeman, TP, Morgan, C & Hindocha, C 2019, 'Strengthening the evidence for medicinal cannabis and cannabinoids', *The BMJ*, vol. 367, l5871, pp. 1-2. <https://doi.org/10.1136/bmj.l5871>

DOI:

[10.1136/bmj.l5871](https://doi.org/10.1136/bmj.l5871)

Publication date:

2019

Document Version

Peer reviewed version

[Link to publication](https://doi.org/10.1136/bmj.l5871)

Copyright © 2019 BMJ Publishing Group. The final publication is available at BMJ via <https://doi.org/10.1136/bmj.l5871>.

University of Bath

Alternative formats

If you require this document in an alternative format, please contact:
openaccess@bath.ac.uk

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Strengthening the evidence for medicinal cannabis and cannabinoids

Tom P Freeman*, Senior Lecturer^{1,2,3,4} t.p.freeman@bath.ac.uk,

Celia Morgan, Professor of Psychopharmacology^{3,5} celia.morgan@exeter.ac.uk,

Chandni Hindocha, Research Fellow^{3,4,6} c.hindocha@ucl.ac.uk

¹ Addiction and Mental Health Group (AIM), Department of Psychology, University of Bath, United Kingdom

² National Addiction Centre, Institute of Psychiatry, Psychology & Neuroscience, King's College London, United Kingdom

³ Clinical Psychopharmacology Unit, Research Department of Clinical, Educational & Health Psychology, University College London, United Kingdom

⁴ Translational Psychiatry Research Group, Research Department of Mental Health Neuroscience, Division of Psychiatry, Faculty of Brain Sciences, University College London, United Kingdom

⁵ Psychopharmacology and Addiction Lab, Department of Psychology, University of Exeter, United Kingdom

⁶ NIHR University College London Hospitals Biomedical Research Centre, University College Hospital, London, United Kingdom

*Corresponding author:

Tom P Freeman, Addiction and Mental Health Group (AIM), Department of Psychology, 10 West, University of Bath, Bath BA2 7AY, United Kingdom

t.p.freeman@bath.ac.uk, +44(0)1225 386639, ORCID ID: <https://orcid.org/0000-0002-5667-507X>

Invited BMJ submission: Editorial

Word count: 786

References: 14

Keywords: Cannabis-based products, THC, CBD, Clinical Trials, Certainty of evidence

Introduction

Draft recommendations by NICE¹ did not recommend prescription of unlicensed cannabis-based products to patients on the NHS. The potential benefits for chronic pain were considered too small in relation to costs, and the quality of evidence was rated too low to make recommendations for severe treatment-resistant epilepsy.¹ At present, the only access to cannabis is through prescriptions at private clinics² (which are prohibitively expensive) or via the illicit market (which carries risk of prosecution). Given the strong demands for access to these products by patients and their carers³ there is an urgent need to strengthen the evidence and to make these products available in cases where they are known to be efficacious and safe.

Cannabis-based medicines vary in their content of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) which have contrasting mechanisms of action, efficacy and safety.⁴ Some cannabis-based medicines include a combination of THC and CBD which can interact with each other when co-administered.⁵ Although Randomised Controlled Trial (RCT) evidence is stronger for certain formulations (such as CBD for severe treatment-resistant epilepsy⁴) patients have expressed a preference for other treatments such as THC combined with CBD.³ Gathering evidence for such treatments is a key priority that can be addressed using novel RCT designs and patient registries.

In order to compare varied cannabis-based products efficiently, RCTs can follow adaptive designs.⁶ For example, patients can be initially randomised to one of several treatment arms such as THC, CBD, or THC combined with CBD. Interim analysis can eliminate treatment arms with poor efficacy or safety at an early stage, while randomisation continues to potentially efficacious doses to strengthen the certainty of evidence.

Cannabis-based products have been investigated for a wide range of possible medical indications, some of which may share common pathologies of the endocannabinoid system.⁷ Where multiple disorders are characterised by the same underlying mechanism, basket trials⁸ can investigate a single targeted intervention across multiple diagnostic categories. Alternatively where different mechanisms are known to give rise to a common medical diagnosis, umbrella trials⁸ can stratify patients into different treatment arms based on underlying disease mechanism and allocate targeted interventions to each group.

Stratification can also occur at the level of the individual patient. N-of-1 trials⁹ use within-patient, randomized, double-blind, crossover comparisons to compare active and control treatments in a cyclical manner. N-of-1 trials can establish cause-effect relationships within an individual to identify efficacy and safety, and the results from multiple patients can be meta-analysed. N-of-1 trials have been successfully applied to cannabis-based products (THC, CBD, or THC combined with CBD) for chronic pain¹⁰ and could be used for severe treatment-resistant epilepsy. They are ideally suited to specific situations such as treatment for compassionate reasons, unlicensed use, and for patients who fail to respond to conventional treatments¹¹ making them especially suitable for investigating cannabis-based medicines in some patients. Classification of a patient as a “responder”⁹ on a case-by-case basis could offer strong evidence for continued prescription.

RCTs are not the only source of evidence. There are many examples of pharmacological treatments for medical indications approved by the EMA and FDA without RCTs.¹² Non-RCT sources of evidence used to support drug approvals include randomised trials without a control group (e.g. different doses of active drug with no placebo), historical control studies, and observational studies.¹² In cases where cannabis-based medicines are provided on private prescription,² patient registries can be used to generate observational data. Such data can be

rapidly generated at minimal cost, and may be compiled with registries outside of the UK such as Canada and Israel to generate large samples of data providing real-world clinical evidence.

Initial public funding to support research on cannabis-based products has been offered through dedicated calls from the National Institute of Health Research. However, the House of Commons Health and Social Care Committee¹³ raised concerns about the unwillingness of industry to provide cannabis-based products for research or to support or conduct clinical trials on their products. Further involvement from industry could increase access to cannabis-based products in a research context without the excessive costs of private prescriptions to patients.² Providing access to cannabis-based products in a research context could offer patients balanced information on their likelihood of benefiting from them according to the evidence at present.

The current low certainty of evidence for cannabis-based products alongside clear patient demand requires novel solutions. Further RCTs for cannabis-based medicines are urgently needed, and novel RCT designs such as N-of-1 trials can provide results that are immediately beneficial for both the patient and clinician.⁹ Like all methodologies, RCTs have their own limitations and relying on these alone may result in biased estimates of effect. Data should be sought from alternative methods such as observational patient registries and triangulated with other methods to develop a robust evidence base.¹⁴

Funding

TPF was funded by a Senior Academic Fellowship from the Society for the Study of Addiction (SSA). CH was supported by the National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre. The views expressed here are those of the authors, and do not reflect those of the University of Bath, the University of Exeter, UCL, the SSA or the NIHR. The funders had no role on the planning, researching or writing of this report or in the decision to submit it for publication.

Competing interests statement

We have read and understood the BMJ Group policy on declaration of interests and declare the following interests: none.

Copyright statement

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence on a worldwide basis to the BMJ Publishing Group Ltd to permit this article to be published in BMJ editions and any other BMJ PGL products and sub-licenses such use and exploit all subsidiary rights, as set out in our licence (bmj.com/advice/copyright.shtml).

1. National Institute for Health and Care Excellence. Cannabis-based medicinal products. <https://www.nice.org.uk/guidance/indevelopment/gid-ng10124/documents>.
2. Mahase E. Medical cannabis: patients turn to private clinics because of NHS void. *Bmj* 2019;366:l5290.
3. Deacon H. Why I campaign for children like my son Alfie Dingley to be able to get medical cannabis. *bmj* 2019;365:l1921.
4. Freeman TP, Hindocha C, Green SF, et al. Medicinal use of cannabis based products and cannabinoids. *BMJ* 2019;365:l1141.
5. Freeman AM, Petrilli K, Lees R, et al. How does cannabidiol (CBD) influence the acute effects of delta-9-tetrahydrocannabinol (THC) in humans? A systematic review. *Neuroscience & Biobehavioral Reviews* in press
6. Berry SM, Carlin BP, Lee JJ, et al. Bayesian adaptive methods for clinical trials: CRC press 2010.
7. Pacher P, Kunos G. Modulating the endocannabinoid system in human health and disease—successes and failures. *The FEBS journal* 2013;280(9):1918-43.
8. Park JJ, Siden E, Zoratti MJ, et al. Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols. *Trials* 2019;20(1):1-10.
9. Lillie EO, Patay B, Diamant J, et al. The n-of-1 clinical trial: the ultimate strategy for individualizing medicine? *Personalized medicine* 2011;8(2):161-73.
10. Notcutt W, Price M, Miller R, et al. Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 'N of 1' studies. *Anaesthesia* 2004;59(5):440-52.
11. Schork NJ. Personalized medicine: time for one-person trials. *Nature News* 2015;520(7549):609.
12. Hatzwell AJ, Baio G, Berlin JA, et al. Regulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FDA approvals 1999–2014. *BMJ open* 2016;6(6):e011666.
13. House of Commons Health and Social Care Committee, 2019. Drugs Policy: Medicinal Cannabis. <https://publications.parliament.uk/pa/cm201719/cmselect/cmhealth/1821/1821.pdf>.
14. Munafò MR, Smith GD. Robust research needs many lines of evidence: Nature Publishing Group, 2018.